First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid TumorsCristiana Sessa, Udai Banerji, Vali Papadimitrakopoulou et al.|Clinical Cancer Research|2013Cited by 160
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationX. Cynthia, Lisa A. Carey, Vera J. Suman et al.|JAMA Oncology|2024Cited by 20
Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphomaAntoine Hollebecque, Monica Mita, Sarit Assouline et al.|Molecular Cancer Therapeutics|2019Cited by 2